ERBB2 and breast carcinoma: In this retrospective study, we aimed to evaluate the prognostic performance of the Stratipath Breast model in predicting distant recurrence (DR) and time to any recurrence (TR) at 10 years, as well as overall survival (OS) over 21 years of follow-up, in postmenopausal Estrogen Receptor (ER)-positive, Human Epidermal Growth factor Receptor 2 (HER2)-negative breast cancer cohort.